Sign inJoin waitlistJoin the waitlist

Sri Obulareddy

Associate Professor · University of Arkansas for Medical Sciences (UAMS) College of Medicine

Credentials: · · · · · · ·

History

University of Arkansas for Medical Sciences (UAMS) College of Medicine
Present

a fellowship in medical oncology
2014–2016
Yashoda Cancer and Multispecialty Center in Hyderabad
2011–2014
Andhra Medical College
2000–2004

Research

Metanephric adenoma of the kidney: an unusual diagnostic challenge
Case report · Rare Tumors · 2010 · First of 6 authors · 11 citations
Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023
Review · Annals of Medicine and Surgery · 2024 · 10 citations
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
American Journal of Clinical Oncology · 2016 · 6 citations

AM
Abinash Mahapatro
2 papers
Arkadiusz Dudek
2 papers
AT
Alexander Truskinovsky
1 paper
AK
Anup Kumar Trikannad Ashwini Kumar
1 paper
Anuradha Kunthur
1 paper
Anusha Jillella
1 paper · 1 as a fellow
Camila Simoes
1 paper
CG
Chitra Ganesan
1 paper
CC
Cristina Corsini Campioli
1 paper
Dhruvan Patel
1 paper
FV
Fnu Vikash
1 paper · 1 as a fellow
GJ
Gautam Jha
1 paper

Clinical trials

Vaccination of High Risk Breast Cancer Patients
Principal investigator · Completed · Phase 1, Phase 2
University of Arkansas
2015–2023
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033